Spruce Biosciences Revenue and Competitors

Daly City, CA USA

Location

$108M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Spruce Biosciences's estimated annual revenue is currently $5M per year.(i)
  • Spruce Biosciences's estimated revenue per employee is $90,182
  • Spruce Biosciences's total funding is $108M.
  • Spruce Biosciences's current valuation is $77.9M. (January 2022)

Employee Data

  • Spruce Biosciences has 55 Employees.(i)
  • Spruce Biosciences grew their employee count by 6% last year.

Spruce Biosciences's People

NameTitleEmail/Phone
1
FounderReveal Email/Phone
2
CEOReveal Email/Phone
3
VP, Pharmaceutical Development and ManufacturingReveal Email/Phone
4
VP, Development OperationsReveal Email/Phone
5
VP, Clinical DevelopmentReveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
President and Chief Financial OfficerReveal Email/Phone
8
Senior Director, FinanceReveal Email/Phone
9
Chief Regulator & Quality OfficerReveal Email/Phone
10
Director Analytical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Spruce Biosciences?

Spruce Biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.

keywords:N/A

$108M

Total Funding

55

Number of Employees

$5M

Revenue (est)

6%

Employee Growth %

$77.9M

Valuation

N/A

Accelerator

Spruce Biosciences News

2022-04-20 - Caliber Associates Recruits Chief Medical Officer for Coherus ...

Dr. Dias most recently served as chief medical officer at Spruce Biosciences Inc. Prior to that, he served as CMO at Indivior PLC.

2022-04-06 - Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at ...

Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Rating) has earned a consensus recommendation of “Buy” from the nine ratings firms that are...

2022-04-06 - Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A. ...

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine...

2021-03-22 - Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Mar 22, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the fou ...

2021-03-17 - Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Mar 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, presented data from its Phase 1 and 2 programs of ti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A58-32%N/A
#2
$17.6M600%N/A
#3
$20.8M7710%N/A
#4
$24.1M832%N/A
#5
$10.8M9014%N/A